2016
Mortality risk from comorbidities independent of triple-negative breast cancer status: NCI-SEER-based cohort analysis
Swede H, Sarwar A, Magge A, Braithwaite D, Cook LS, Gregorio DI, Jones BA, R. Hoag J, Gonsalves L, L. Salner A, Zarfos K, Andemariam B, Stevens RG, G. Dugan A, Pensa M, A. Brockmeyer J. Mortality risk from comorbidities independent of triple-negative breast cancer status: NCI-SEER-based cohort analysis. Cancer Causes & Control 2016, 27: 627-636. PMID: 27000206, PMCID: PMC5591028, DOI: 10.1007/s10552-016-0736-3.Peer-Reviewed Original ResearchConceptsCharlson co-morbidity indexRisk of deathBreast cancer patientsB patientsCCI scoreHazard ratioCancer patientsTriple-negative breast cancer subtypeTriple-negative breast cancer statusWhite breast cancer patientsCo-morbidity indexConnecticut Tumor RegistryEstimated hazard ratioBreast cancer statusBreast cancer subtypesAA/BCause mortalityClinicopathological factorsTumor RegistryAmerican/BlackCancer populationHigh prevalenceBreast cancerCohort analysisCancer status
2009
Patterns of HER2 testing in the management of primary breast cancer
Pensa M, Swede H, Brockmeyer JA, Gregorio DI. Patterns of HER2 testing in the management of primary breast cancer. Cancer Epidemiology 2009, 33: 113-117. PMID: 19679057, DOI: 10.1016/j.canep.2009.06.010.Peer-Reviewed Original ResearchConceptsLymph node statusHER2 testingNode statusTumor gradeBreast cancerHuman epidermal growth factor receptor 2 (HER2) statusEpidermal growth factor receptor 2 statusPrimary invasive breast carcinomasWhite womenReceipt of testingConnecticut Tumor RegistryYear of diagnosisInvasive breast cancerPopulation-based patternsPrimary breast cancerTime of diagnosisBreast cancer patientsEstrogen receptor statusTumors of patientsInvasive breast carcinomaAfrican American womenWomen’s prognosisClinicopathologic factorsER statusReceptor status